This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Intellia's (NTLA) Q4 Loss Matches Estimates, Revenues Up Y/Y
by Zacks Equity Research
Intellia Therapeutics (NTLA) reports loss for fourth-quarter 2022, in line with estimates.
REGNNegative Net Change BGNEPositive Net Change NTLANegative Net Change ALLONegative Net Change
biotechnology crispr medical
Prothena (PRTA) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Prothena (PRTA) reports better-than-expected results for the fourth quarter. The company makes considerable pipeline progress.
RHHBYNegative Net Change BMYPositive Net Change NVOPositive Net Change PRTANegative Net Change
biotechnology pharmaceuticals
Perion Network and West Fraser Timber have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Perion Network and West Fraser Timber are part of the Zacks Bull and Bear of the Day article.
MRNANegative Net Change PERINegative Net Change AGIONegative Net Change BHCPositive Net Change WFGNegative Net Change
agriculture biotechnology consumer-discretionary pharmaceuticals
The Zacks Analyst Blog Highlights JPMorgan Chase, Elevance Health, Vertex Pharmaceuticals, Sony Group and General Mills
by Zacks Equity Research
JPMorgan Chase, Elevance Health, Vertex Pharmaceuticals, Sony Group and General Mills are part of the Zacks top Analyst Blog.
JPMPositive Net Change GISPositive Net Change VRTXNegative Net Change SONYNegative Net Change ELVPositive Net Change
biotechnology consumer-discretionary consumer-staples finance medical
Top Stock Reports for JPMorgan Chase, Elevance Health & Vertex Pharmaceuticals
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Elevance Health, Inc. (ELV) and Vertex Pharmaceuticals Incorporated (VRTX).
JPMPositive Net Change GISPositive Net Change VRTXNegative Net Change AMENegative Net Change SONYNegative Net Change ELVPositive Net Change
biotechnology finance medical
Regeneron (REGN) Rare Disease Drug Gets FDA's Priority Review
by Zacks Equity Research
Regeneron's (REGN) application seeking approval of pozelimab for the ultra-rare hereditary immune disease CHAPLE gets Priority Review by the FDA.
REGNNegative Net Change ALNYNegative Net Change BAYRYPositive Net Change
biotechnology pharmaceuticals
Hercules Technology (HTGC) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
HTGCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Banco Do Brasil SA (BDORY) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
BDORYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Dassault Systemes SA (DASTY) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
DASTYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Gilead (GILD) Reports Positive Data From Urothelial Cancer Study
by Zacks Equity Research
Gilead's (GILD) new and updated positive results from a phase II study show Trodelvy's rapid and durable responses for patients across a range of hard-to-treat types of mUC.
GSKPositive Net Change DVAXNegative Net Change GILDPositive Net Change KALAPositive Net Change
biotechnology biotechs pharmaceuticals
Manhattan Associates (MANH) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
MANHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
8x8 (EGHT) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
EGHTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy NGL Energy Partners LP (NGL) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
NGLPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
5 Large-Cap Stocks Set to Beat on Q4 Earnings This Week
by Nalak Das
The following five large-cap stocks are set to beat Q4 earnings estimates this week. These are: TECK, LECO, NI, EXAS and GFL.
NIPositive Net Change LECONegative Net Change EXASPositive Net Change TECKPositive Net Change GFLPositive Net Change
basic-materials biotechnology business-services industrial-products utilities
Ultragenyx (RARE) Q4 Earnings Miss, Revenues Increase Y/Y
by Zacks Equity Research
Ultragenyx (RARE) reports a wider loss in the fourth quarter while revenues increase on growth in demand for its drugs.
DVAXNegative Net Change RARENegative Net Change KALAPositive Net Change VIRNegative Net Change
biotechnology earnings
Biotech Stock Roundup: BIIB's Q4 Results, EBS and BPMC Offer Updates
by Zacks Equity Research
Earnings results from Biogen (BIIB) and updates from EBS are the key highlights from the biotech sector during the past week.
BIIBNegative Net Change EBSNegative Net Change
biotechnology biotechs
Toronto-Dominion Bank (TD) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
TDPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Playa Hotels & Resorts (PLYA)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Splunk (SPLK) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
SPLKPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
LightPath Technologies, Inc. (LPTH)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
LPTHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Exelixis (EXEL), Sairopa Obtains IND Clearance for ADU-1805
by Zacks Equity Research
Exelixiss' EXEL) partner Sairopa gets FDA clearance for its IND application for the oncology drug ADU-1805, a potential best-in-class monoclonal antibody for adults with advanced solid tumors.
BMYPositive Net Change DVAXNegative Net Change ALKSPositive Net Change EXELNegative Net Change
biotechnology biotechs pharmaceuticals
Top Research Reports for Chevron, Novo Nordisk & Amgen
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Novo Nordisk A/S (NVO) and Amgen Inc. (AMGN).
GDNegative Net Change CVXPositive Net Change NVOPositive Net Change AMGNPositive Net Change SBUXNegative Net Change RMDNegative Net Change
biotechnology medical oil-energy pharmaceuticals
BJ's Wholesale Club (BJ)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
BJPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
New Strong Buy Stocks for February 14th
by Zacks Equity Research
INSP, ALK, SSKN, NVO and TBPH have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.
NVOPositive Net Change ALKNegative Net Change TBPHNegative Net Change SSKNPositive Net Change INSPPositive Net Change
biotechnology medical
Incyte (INCY) Reports Positive Long-Term Data From HS Study
by Zacks Equity Research
Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.
NVSNegative Net Change DVAXNegative Net Change ALKSPositive Net Change INCYPositive Net Change
biotechnology biotechs pharmaceuticals